A Study to Evaluate the Safety and Efficacy of PV-001-DV in Combination With Infusion of PV-001-DC in Patients With Advanced Melanoma
Latest Information Update: 10 Jul 2023
At a glance
- Drugs PV 001 DV (Primary) ; PV-001-DC (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors PrimeVax Immuno-Oncology
- 04 Jul 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 04 Jul 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2024.
- 04 Jul 2023 Planned initiation date changed from 1 Apr 2023 to 1 Apr 2024.